340B Providers Blindsided by Bausch Health’s Decision to Drop AmerisourceBergen as Distributor

340B covered entities are scrambling to respond to the fallout from Bausch Health's surprise announcement that it ended its relationship with AmerisourceBergen to distribute its 340B-priced branded products. | Source: Shutterstock

Drug manufacturer Bausch Health blindsided 340B covered entities on New Year’s Eve, announcing that starting the very next day, Jan. 1, more than 200 of its branded products and future branded products would no longer be available through distributor AmerisourceBergen

Read More »

Senate Democratic Chairs-in-Waiting Waste No Time Going to Bat for 340B Providers

The incoming Democratic chairs of two key U.S. Senate committees want the federal agency in charge of the 340B program “to take immediate action to clarify that implementation of a rebate model by [drug] manufacturers would violate a material condition

Read More »

Providers Are Pleased, PhRMA Isn’t, With Becerra and State AGs’ 340B Letter to Azar

Editor’s note—A cascade of breaking 340B news developments over the past seven days—Amgen’s orphan drug action, HRSA’s dispute resolution final rule, the hospital lawsuit against HHS, the state attorneys general letter to HHS and the new GAO report—forced us to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live